Cemiplimab

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the…

Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in…

<!-- Name:DistributionId Value:8756353 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

PARIS -- Neoadjuvant therapy with cemiplimab (Libtayo) achieved deep pathologic responses in patients with resectable cutaneous…

Physician’s Briefing Staff MONDAY, Sept. 12, 2022 (HealthDay News) -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for…